Core Points - A class action lawsuit has been filed against Quantum Corporation (NASDAQ: QMCO) for allegedly making false and misleading statements regarding its financial practices [3][7] - The lawsuit claims that Quantum improperly recognized revenue for the fiscal year ended March 31, 2025, necessitating a restatement of financial statements for the fiscal third quarter ended December 31, 2024 [3][7] - Investors who acquired Quantum securities between November 15, 2024, and August 18, 2025, are encouraged to contact the law firm Bragar Eagel & Squire for potential legal recourse [4][7] Allegation Details - The lawsuit alleges that Quantum Corporation's statements about its business, operations, and prospects were materially false and misleading due to improper revenue recognition [3] - The failure to disclose these issues resulted in damages to investors when the true details became public [3] Next Steps - Investors who suffered losses and wish to learn more about the claims or have questions are advised to contact the law firm directly [4] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 3, 2025 [7]

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit alleges that Unicycive's management assured investors of the company's ability to satisfy FDA requirements, which was later revealed to be overstated [8] - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in compliance at a third-party manufacturing vendor, leading to a stock price drop of over 40% [8] - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock fell nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [4] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Encompass Health Corporation for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is prompted by allegations that Encompass's for-profit hospitals perform below average on key safety measures, as reported by The New York Times [6]. - Specific concerns include that Encompass owns facilities with significantly worse rates of potentially preventable readmissions, with 34 facilities rated poorly by Medicare [6]. Stock Impact - Following the publication of the allegations, Encompass's stock price dropped by $12.39, or 10.4%, closing at $107.28 per share on July 15, 2025, indicating a direct financial impact on investors [6].

Core Viewpoint - A class action lawsuit has been filed against Dow, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial condition during the specified class period from January 30, 2025, to July 23, 2025 [1][7]. Allegation Details - Defendants are accused of overstating Dow's ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [3]. - The negative impacts of competitive pressures, declining global sales, and product oversupply on Dow's business were allegedly understated [3]. - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Dow shares and experienced losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a recognized law firm that represents individual and institutional investors in various complex litigations across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the specified class period from February 18, 2025, to July 31, 2025 [3][7]. Allegation Details - The complaint alleges that Fluor's management failed to disclose significant cost increases related to major projects, including the Gordie Howe, I-635/LBJ, and I-35 projects, due to subcontractor design errors, price increases, and scheduling delays [3]. - It is claimed that these issues, along with reduced capital spending from customers and economic uncertainty, were likely to have a significant negative impact on Fluor's business and financial results [3]. - The financial guidance provided by Fluor for FY 2025 is described as unreliable and unrealistic, with an overstated effectiveness of the company's risk mitigation strategy and an understated impact of economic uncertainty [3]. Next Steps - Investors who purchased Fluor shares and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 14, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors during the specified class period [8]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements while concealing material adverse facts about the company's advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April [8]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with their ad platform and other factors [8]. Stock Price Impact - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [8]. Next Steps for Investors - Investors who purchased Snap shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PubMatic (PUBM) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in PubMatic between February 27, 2025 and August 11, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- What’s Happenin ...

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentations regarding its New Drug Application for oxylanthanum carbonate [7] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [7] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [7] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [7] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [7] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price decline of almost 30%, closing at $4.77 per share [7] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4][8] - The law firm represents individual and institutional investors in complex litigation across the United States [5]

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors during the specified class period [8]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements while concealing material adverse facts about the company's advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April [8]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with their ad platform and other factors [8]. Stock Price Impact - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [8]. Next Steps for Investors - Investors who purchased Snap shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 20, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against KinderCare Learning Companies, Inc. for allegedly misleading investors regarding the quality of care provided at its facilities and undisclosed risks associated with its IPO [1][6]. Allegation Details - The lawsuit claims that the registration statement for KinderCare's IPO was false and/or misleading, failing to disclose incidents of child abuse, neglect, and harm at its facilities [6]. - It is alleged that KinderCare did not provide the "highest quality care possible" and failed to meet basic standards in the child care industry, exposing the company to material risks including lawsuits and reputational damage [6]. Stock Performance - Following the IPO, KinderCare's stock price has reportedly fallen to lows near $9 per share, indicating a significant decline in investor confidence [6].